Vanishing bile duct syndrome in a patient with multiple myeloma treated with bortizomib, lenalidomide and dexamethasone

Clin Res Hepatol Gastroenterol. 2023 Oct;47(8):102198. doi: 10.1016/j.clinre.2023.102198. Epub 2023 Aug 19.

Authors

Kalman Filanovsky¹, Nadya Temper², Anfisa Stanevsky³, Lev Shvidel³

Affiliations

¹ Kaplan Medical Center, Department of Hematology, Rehovot, Israel, affiliated with the Hebrew University, Jerusalem, Israel. Electronic address: fikalman@yahoo.com.
² Kaplan Medical Center, Pathology Department, Rehovot, Israel, affiliated with the Hebrew University, Jerusalem, Israel.
³ Kaplan Medical Center, Department of Hematology, Rehovot, Israel, affiliated with the Hebrew University, Jerusalem, Israel.

PMID: 37598809
DOI: 10.1016/j.clinre.2023.102198

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Bile Ducts
Cholestasis*
Dexamethasone / adverse effects
Humans
Lenalidomide / therapeutic use
Multiple Myeloma* / complications
Multiple Myeloma* / drug therapy
Thalidomide / adverse effects

Substances

Lenalidomide
Thalidomide
Dexamethasone